Alembic Pharmaceuticals Recommends 600% Dividend; Q4 FY26 PAT Surges 53% QoQ to ₹202 Cr

Synopsis: Alembic Pharmaceuticals Ltd reported a mixed operational performance for Q4 FY26, with revenue growth remaining steady while profitability witnessed a sharp sequential jump. The company posted a strong rise in net profit during the quarter, supported by lower tax outgo and stable business performance across domestic and international markets. 

Alembic Pharmaceuticals Ltd is one of India’s leading pharmaceutical companies engaged in the development, manufacturing, and marketing of generic formulations, active pharmaceutical ingredients (APIs), and specialty pharmaceutical products. The company has a strong presence across domestic and global markets, particularly in the US generics business. With decades of operational experience, Alembic continues to strengthen its product portfolio, manufacturing capabilities, and research-driven operations across key therapeutic segments. 

Alembic Pharmaceuticals Ltd currently commands a market capitalization of Rs. 14,301 crore. The stock is trading at Rs. 716 per share down by 9% compared to its previous close of Rs. 784, compared to its 52-week high of Rs. 1,108 and 52-week low of Rs. 635. 

The company has a stock P/E ratio of 19.6 times, while its ROCE and ROE stand at 12.6 percent and 13.4 percent respectively. Alembic Pharmaceuticals also offers a dividend yield of 1.49 percent. 

Alembic Pharmaceuticals reported revenue of Rs. 1,848 crore in Q4 FY26, compared to Rs. 1,876 crore in Q3 FY26, reflecting a marginal decline of around 1.5 percent on a sequential basis. However, on a year-on-year basis, revenue increased by nearly 4 percent from Rs. 1,770 crore reported in Q4 FY25. 

The company’s operating profit stood at Rs. 228 crore during the quarter, compared to Rs. 292 crore in Q3 FY26 and Rs. 271 crore in Q4 FY25. Operating profit margin declined to 12 percent in Q4 FY26 from 16 percent in the previous quarter, mainly due to higher operating expenses. 

Profit before tax came in at Rs. 119 crore, registering a decline of around 27 percent sequentially from Rs. 162 crore in Q3 FY26. On a year-on-year basis, PBT fell nearly 38 percent from Rs. 192 crore reported during Q4 FY25. 

Despite lower operating profitability, net profit surged to Rs. 202 crore in Q4 FY26, compared to Rs. 132 crore in Q3 FY26 and Rs. 157 crore in Q4 FY25. This represents a strong growth of approximately 53 percent quarter-on-quarter and nearly 29 percent year-on-year. Earnings per share (EPS) also improved significantly to Rs. 10.31 from Rs. 6.76 in the previous quarter. 

Alembic Pharmaceuticals recommended a final dividend of Rs. 12 per equity share having a face value of Rs. 2 each for FY26. The payout translates into a 600 percent dividend and is subject to shareholder approval at the upcoming Annual General Meeting. 

Alembic Pharmaceuticals reported stable revenue in Q4 FY26, but operating profit and margins declined due to higher expenses and weaker operational performance. The company, however, received a significant tax rebate, which boosted net profit sharply to Rs. 202 crore during the quarter. Despite the rise in profitability, investors remained concerned about the weak core business performance, resulting in nearly an 8 percent decline in the company’s share price after the quarterly results announcement. 

Industry Outlook 

India’s pharmaceutical industry is expected to grow strongly, with the market projected to rise from Rs. 4.71 lakh crore (US$55 billion) in 2025 to Rs. 10.28-11.13 lakh crore (US$120-130 billion) by 2030. The industry turnover reached Rs. 2.25 lakh crore in FY25, supported by rising demand for generic medicines, vaccines, and specialty drugs. 

Government support also remains strong for the sector. The PLI scheme has an outlay of Rs. 15,000 crore, while the Department of Pharmaceuticals received Rs. 5,268 crore allocation for FY26. India’s pharma sector also attracted FDI inflows worth Rs. 2.10 lakh crore between April 2000 and June 2025. 

Alembic Pharmaceuticals delivered steady revenue growth during Q4 FY26 while reporting a sharp improvement in bottom-line performance. Although operating margins remained under pressure, the company’s strong profit growth and generous 600 percent dividend announcement highlighted management’s confidence in long-term business fundamentals. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Alembic Pharmaceuticals Recommends 600% Dividend; Q4 FY26 PAT Surges 53% QoQ to ₹202 Cr appeared first on Trade Brains.